NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company’s web site at www.neurogesx.com
- 17 years ago
QualityStocks
NeurogesX, Inc. (NASDAQ: NTII)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – XTI Aerospace, Inc. (NASDAQ: XTIA) Highlights Revenue Visibility and Operating Leverage at Shareholder Town Hall
XTI Aerospace (NASDAQ: XTIA), an aerospace technology company focused on scaling its Drone Nerds, LLC subsidiary,…
-
Safe Pro Group Inc. (NASDAQ: SPAI) Will Highlight the Company’s AI Capabilities for Military Engineers at Upcoming 2026 Defence Leaders Combat Engineer & Logistics Conference
Safe Pro Group will present at the 2026 Defence Leaders Combat Engineer & Logistics Conference…
-
LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Aligns Liora and the LiGHT System With LB-100 to Push the Frontier of Cancer Treatment
LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This…